| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―May―25 |
Disulfide bond formation between Cys22 and Cys44 in SARS-CoV-2 main protease |
Lauren R. Blankenship, Kai Yang, Chia-Chuan Dean Cho, Yi-Ju Penny Chen, Banumathi Sankaran, Wenshe Ray Liu |
| 2 |
[GO] |
2026―Apr―17 |
SARS-CoV-2 main protease inhibition by natural compounds |
Gisele Strieder Philippsen, Lucas Yudai Nozaki, Michael Jackson Vieira da Silva, Juliana Nakamura, Erika Seki Kioshima, Fernanda Andreia Rosa, Flavio Augusto Vicente Seixas |
| 3 |
[GO] |
2026―Mar―11 |
Optimization of pyridopyrimidinedione derivatives as non-covalent SARS-CoV-2 3CL protease inhibitors |
Yoshiyuki Taoda, Keiichiro Hirai, Shuichi Sugiyama, Satoru Tanaka, Yutaka Tomida, Toshiyuki Akiyama, Kenji Nakahara, Yuto Unoh, Yuki Tachibana, Shota Uehara, Yusuke Sako, Shiho Yamamoto, Sho Kawashima, Haruki Nobori, Teruhisa Kato |
| 4 |
[GO] |
2026―Mar―04 |
Aryl-functionalized mono- and diketone curcumin derivatives inhibit SARS-CoV-2 Spike:ACE2 interactions |
Jeremiah Gabriel G. Africa, Kyra Danielle C. Magdato, Monissa C. Paderes |
| 5 |
[GO] |
2025―Dec―08 |
Identification of flavonoid-based small molecule inhibitors with dual-targeting capability against RdRp and Mpro of SARS-CoV-2 |
Yanlei Su, Yujia Wang, Jianyuan Zhao, Keyu Guo, Xuhong Duan, Honghai Wu, Dianxing Sun, Jing Zhang, Shan Cen |
| 6 |
[GO] |
2025―Sep―10 |
Design, synthesis and biological evaluation of novel quinazolinedione derivatives as non-covalent SARS-CoV-2 3CL protease inhibitors |
Yoshiyuki Taoda, Akihiro Hori, Genta Tadano, Shuichi Sugiyama, Sota Masakado, Satoru Tanaka, Riku Ogasahara, Kenji Nakahara, Shomitsu Maeno, Yuto Unoh, Yuki Tachibana, Shota Uehara, Yusuke Sako, Shiho Yamamoto, Sho Kawashima, Haruki Nobori, Teruhisa Kato |
| 7 |
[GO] |
2025―Apr―17 |
Mini review: SHEN26, a novel oral antiviral drug for COVID-19 treatment |
Peisen Zheng, Guanguan Li, Yuanguang Chen, Shuo Li, Sidi Yang, Deyin Guo, Qifan Zhou, Xumu Zhang |
| 8 |
[GO] |
2025―Mar―27 |
Discovery of 4-((quinolin-8-ylthio)methyl)benzamide derivatives as a new class of SARS-CoV-2 nsp13 inhibitors |
Danchen Fan, Yuanting Huang, Rui Yao, Guo Zhang, Shengyong Yang, Linli Li |
| 9 |
[GO] |
2025―Mar―11 |
Research progress on critical viral protease inhibitors for coronaviruses and enteroviruses |
Shulei Hu, Qiuyu Zhong, Xiong Xie, Shurui Zhang, Jinlin Wang, Hong Liu, Wenhao Dai |
| 10 |
[GO] |
2025―Mar―06 |
Discovery of Flavonol derivatives as porcine reproductive and respiratory syndrome virus inhibitors |
Zhi-Zheng Wang, Chen-Xu Xiao, Wen-Li Huang, Yang Hu, Hui-Ting Zhang, Zhang Liu, Sheng-Hao Peng, Zigong Wei |
| 11 |
[GO] |
2024―Nov―21 |
Synthesis and Structure-Activity relationship of covalent inhibitors of SARS-CoV-2 papain-like protease with antiviral potency |
Catherine C. Rouch, Arnab K. Chatterjee, Connor McCarty, Lirui Song, Alan Chu, Kristen Johnson, Mina Heacock, Laura Riva, Case W. McNamara, Karen C. Wolff, Rebecca Greene-Cramer, Anna De Falco, Gaetano T. Montelione, Gennadii A. Grabovyi |
| 12 |
[GO] |
2024―Nov―01 |
Synthesis and evaluation of N-arylindazole-3-carboxamide derivatives as novel antiviral agents against SARS-CoV-2 |
Jun Young Lee, Sangeun Jeon, Jung-Eun Cho, Sungmin Kim, Hyoung Rae Kim, Hyeung-geun Park, Seungtaek Kim, Chul Min Park |
| 13 |
[GO] |
2024―Nov―01 |
Structural basis of the C-terminal domain of SARS-CoV-2 N protein in complex with GMP reveals critical residues for RNA interaction |
Xincheng Ni, Yinze Han, Jiao Yu, Renjie Zhou, Jian Lei |
| 14 |
[GO] |
2024―Oct―31 |
Design, synthesis, and biological evaluation of dithiocarbamate derivatives as SARS-CoV-2 Mpro inhibitors |
Jin-Qi Peng, Ya-Qi Xiao, Jiao Long, Shuang-Shuang Zhang, Yuan-Yuan Zhu, Shuang-Xi Gu |
| 15 |
[GO] |
2024―Sep―07 |
Assessing the inhibitory effects of some secondary amines, thioureas and 1,3-dimethyluracil conjugates of (-)-cytisine and thermopsine on the RNA-dependent RNA polymerase of SARS-CoV-1 and SARS-CoV-2 |
Yeh Chen, Mann-Jen Hour, Chen-Sheng Lin, Young-Sheng Chang, Zan-Yu Chen, Alena V. Koval’skaya, Wen-Chi Su, Inna P. Tsypysheva, Cheng-Wen Lin |
| 16 |
[GO] |
2024―Aug―30 |
Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease |
Wen Shen, Xinyao Chen, Liping Zhou, Yan Cheng, Yan Zhang, Xiangrui Jiang, Haiguo Sun, Jingshan Shen |
| 17 |
[GO] |
2024―Aug―16 |
Inhibitors of Rickettsia prowazekii methionine aminopeptidase 1 identified from the Pandemic Response Box |
Ishpriya Sharma, Drashti Daraji, James R. Horn, Timothy J. Hagen |
| 18 |
[GO] |
2024―Jun―25 |
Machine learning-based QSAR and LB-PaCS-MD guided design of SARS-CoV-2 main protease inhibitors |
Borwornlak Toopradab, Wanting Xie, Lian Duan, Kowit Hengphasatporn, Ryuhei Harada, Silpsiri Sinsulpsiri, Yasuteru Shigeta, Liyi Shi, Phornphimon Maitarad, Thanyada Rungrotmongkol |
| 19 |
[GO] |
2024―Mar―19 |
An ascidian Polycarpa aurata-derived pan-inhibitor against coronaviruses targeting Mpro |
Jing Zhang, Lili Zhao, Yuxin Bai, Shanshan Li, Meifang Zhang, Bo Wei, Xianyang Wang, Yan Xue, Li Li, Guiliang Ma, Yu Tang, Xin Wang |
| 20 |
[GO] |
2024―Feb―27 |
Synthesis, SARS-CoV-2 main protease inhibition, molecular docking and in silico ADME studies of furanochromene-quinoline hydrazone derivatives |
Blake M. Shellenberger, Olivia N. Basile, Joel Cassel, Morgan R. Olsen, Joseph M. Salvino, Luis J. Montaner, Ian Tietjen, Geneive E. Henry |
| 21 |
[GO] |
2024―Feb―21 |
Discovery of an ellipticine derivative as TLR3 inhibitor against influenza A virus and SARS-CoV-2 |
Yue Pan, Qiuyue Fu, Yinyan Li, Jie Yang, Kui Cheng |
| 22 |
[GO] |
2024―Feb―02 |
Exploring 2-methyl-substituted vitamin K3 derivatives with potent inhibitory activity against the 3CL protease of SARS-CoV-2 |
Ryohto Koharazawa, Mayu Hayakawa, Kazuki Takeda, Kotone Miyazaki, Chisato Tode, Yoshihisa Hirota, Yoshitomo Suhara |
| 23 |
[GO] |
2023―Nov―24 |
Design of MERS-CoV entry inhibitory short peptides based on helix-stabilizing strategies |
Jichun Li, Qing Li, Shuai Xia, Jiahuang Tu, Longbo Zheng, Qian Wang, Shibo Jiang, Chao Wang |
| 24 |
[GO] |
2023―Nov―08 |
Discovery of 3-oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin derivatives as SARS-CoV-2 main protease inhibitors through virtual screening and biological evaluation |
Xiaodong Dou, Qi Sun, Yameng Liu, Yangbin Lu, Caifang Zhang, Guofeng Xu, Yue Xu, Tongyu Huo, Xinyi Zhao, Lingyu Su, Yihong Xing, Luhua Lai, Ning Jiao |
| 25 |
[GO] |
2023―Oct―20 |
Pyrazolidinone-Based Peptidomimetic SARS-CoV-2 Mpro inhibitors |
Daniels Jelisejevs, Anna Lina Bula, Linda Kinena |
| 26 |
[GO] |
2023―Sep―27 |
SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads |
Arun K. Ghosh, Dana Shahabi, Mackenzie E.C. Imhoff, Satish Kovela, Ashish Sharma, Shin-ichiro Hattori, Nobuyo Higashi-Kuwata, Hiroaki Mitsuya, Andrew D. Mesecar |
| 27 |
[GO] |
2023―Jul―11 |
Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV-2 main protease |
Falu Wang, Rui Zeng, Jingxin Qiao, Anjie Xia, Yueshan Li, Feng Li, Yunjie Wu, Yuanzhi Liu, Xiu Zhao, Jian Lei, Shengyong Yang |
| 28 |
[GO] |
2023―May―12 |
Discovery of Novel Bicyclic[3.3.0]proline Peptidyl α-Ketoamides as Potent 3CL-Protease Inhibitors for SARS-CoV-2 |
Xiaoxin Chen, Peng Li, Jianzhou Huang, Yaxun Yang, Haoyu Zhang, Zheng Wang, Zhenzhen Zhu, Jingjing Wang, Jianchen Zhang, Kevin Chen, Haiying He, Chaofeng Long, Shuhui Chen |
| 29 |
[GO] |
2023―Mar―15 |
Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors |
Nihong Guo, Chong Huang, Jinxin Qiao, Yueyue Li, Yifei Wang, Anjie Xia, Guo Zhang, Zhen Fang, Jing You, Linli Li |
| 30 |
[GO] |
2023―Mar―02 |
Discovery of 2-Aminoquinolone Acid Derivatives as Potent Inhibitors of SARS-CoV-2 |
Young Sup Shin, Jun Young Lee, Sangeun Jeon, Subeen Myung, Hyun June Gong, Seungtaek Kim, Hyoung Rae Kim, Lak Shin Jeong, Chul Min Park |
| 31 |
[GO] |
2023―Mar―01 |
Hydroxy-xanthones as promising antiviral agents: Synthesis and biological evaluation against human coronavirus OC43 |
Bethanie Dean, Gemma Cooper, Maitreyi Shivkumar, Timothy J. Snape |
| 32 |
[GO] |
2023―Feb―08 |
Synthesis and biological evaluation of new β-D-N4-hydroxycytidine analogs against SARS-CoV-2, influenza viruses and DENV-2 |
Yeon Jin An, Se Myeong Choi, Eun Rang Choi, Ye Eun Nam, Eun Woo Seo, Soo Bin Ahn, Yejin Jang, Meehyein Kim, Jong Hyun Cho |
| 33 |
[GO] |
2022―Dec―29 |
Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease |
Daiki Katagishi, Daisuke Yasuda, Kyoko Takahashi, Shigeo Nakamura, Tadahiko Mashino, Tomoyuki Ohe |
| 34 |
[GO] |
2022―Sep―14 |
COVID-19: Vaccines and therapeutics |
Swapna Ponnampalli, Naga Venkata Suryanarayana Birudukota, Ahmed Kamal |
| 35 |
[GO] |
2022―Jun―24 |
Discovery of 2-Thiobenzimidazoles as Noncovalent Inhibitors of SARS-CoV-2 Main Protease |
Davide Deodato, Nadeem Asad, Timothy M. Dore |
| 36 |
[GO] |
2022―Apr―12 |
Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors |
Emily G. Hicks, Sylvie E. Kandel, Jed N. Lampe |
| 37 |
[GO] |
2022―Feb―16 |
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir |
Sven Ullrich, Kasuni B. Ekanayake, Gottfried Otting, Christoph Nitsche |
| 38 |
[GO] |
2022―Jan―05 |
Discovery of highly potent SARS-CoV-2 Mpro inhibitors based on benzoisothiazolone scaffold |
Weixiong Chen, Bo Feng, Sheng Han, Peipei Wang, Wuhong Chen, Yi Zang, Jia Li, Youhong Hu |
| 39 |
[GO] |
2021―Aug―19 |
Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors |
Sven Ullrich, Vishnu M. Sasi, Mithun C. Mahawaththa, Kasuni B. Ekanayake, Richard Morewood, Josemon George, Laura Shuttleworth, Xiaobai Zhang, Cassidy Whitefield, Gottfried Otting, Colin Jackson, Christoph Nitsche |
| 40 |
[GO] |
2021―Jul―14 |
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors |
Subramanyam Vankadara, Yun Xuan Wong, Boping Liu, Yi Yang See, Li Hong Tan, Qian Wen Tan, Gang Wang, Ratna Karuna, Xue Guo, Shu Ting Tan, Jia Yi Fong, Joma Joy, C.S. Brian Chia |
| 41 |
[GO] |
2021―May―03 |
Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library |
Joo-Youn Lee, Chih-Jung Kuo, Jin Soo Shin, Eunhye Jung, Po-Huang Liang, Young-Sik Jung |
| 42 |
[GO] |
2021―May―01 |
Exploring the potential of novel phenolic compounds as potential therapeutic candidates against SARS-CoV-2, using quantum chemistry, molecular docking and dynamic studies |
Maimoona Zia, Shabbir Muhammad, Shamsa Bibi, Sumra Wajid Abbasi, Abdullah G. Al-Sehemi, Aijaz Rasool Chaudhary, Fu Quan Bai |
| 43 |
[GO] |
2021―Apr―20 |
Development of ciclesonide analogues that block SARS-CoV-2 RNA replication |
Genichiro Tsuji, Kenzo Yonemitsu, Takahito Ito, Yuta Yanase, Masashi Uema, Nobumichi Ohoka, Takao Inoue, Hiroshi Asakura, Yosuke Demizu |
| 44 |
[GO] |
2021―Mar―26 |
Identification of Non-Covalent SARS-CoV-2 Main Protease Inhibitors by a Virtual Screen of Commercially Available Drug-Like Compounds |
Linlin Zhang, McClane Howland, Rolf Hilgenfeld, Marc O. Anderson, Scott Eagon |
| 45 |
[GO] |
2021―Mar―20 |
SARS-CoV-2 main protease inhibition by compounds isolated from Luffa cylindrica using molecular docking |
Thao Quyen Cao, Jeong Ah Kim, Mi Hee Woo, Byung Sun Min |
| 46 |
[GO] |
2021―Mar―07 |
Application of Niclosamide and Analogs as Small Molecule Inhibitors of Zika Virus and SARS-Cov-2 Infection |
Khalida Shamim, Miao Xu, Xin Hu, Emily M Lee, Xiao Lu, Ruili Huang, Pranav Shah, Xin Xu, Catherine Z Chen, Min Shen, Hui Guo, Lu Chen, Zina Itkin, Richard Eastman, Paul Shinn, Carleen Klumpp-Thomas, Sam Michael, Anton Simeonov, Donald C. Lo, Guo-li Ming, Hongjun Song, Hengli Tang, Wei Zheng, Wenwei Huang |
| 47 |
[GO] |
2021―Mar―02 |
Design, Synthesis and Biological Evaluation of 2-Aminoquinazolin-4(3H)-one Derivatives as Potential SARS-CoV-2 and MERS-CoV Treatments |
Jun Young Lee, Young Sup Shin, Sangeun Jeon, Se In Lee, Soojin Noh, Jung-Eun Cho, Min Seong Jang, Seungtaek Kim, Jong Hwan Song, Hyoung Rae Kim, Chul Min Park |
| 48 |
[GO] |
2020―Nov―05 |
Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2 |
Young Sup Shin, Jun Young Lee, Soojin Noh, Yoonna Kwak, Sangeun Jeon, Sunoh Kwon, Young-hee Jin, Min Seong Jang, Seungtaek Kim, Jong Hwan Song, Hyoung Rae Kim, Chul Min Park |
| 49 |
[GO] |
2020―Aug―08 |
Identification of 4-Anilino-6-aminoquinazoline Derivatives as Potential MERS-CoV Inhibitors |
Jun Young Lee, Young Sup Shin, Jihye Lee, Sunoh Kwon, Young-hee Jin, Min Seong Jang, Seungtaek Kim, Jong Hwan Song, Hyoung Rae Kim, Chul Min Park |
| 50 |
[GO] |
2020―Jul―02 |
The SARS-CoV-2 main protease as drug target |
Sven Ullrich, Christoph Nitsche |
|
